Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542950 | 0.89 | TSHR (0.38) | TSHRLMNATDP1ALDH1A1FABP4 | |
| SCHEMBL12225748 | 0.83 | FABP4 (0.44) | TSHRLMNATDP1ALDH1A1FABP4 | |
| SCHEMBL13545055 | 0.82 | LMNA (0.36) | TSHRLMNATDP1ALDH1A1FABP4 | |
| SCHEMBL13542951 | 0.78 | CA12 (0.48) | LMNATDP1ALDH1A1FABP4L3MBTL1 | |
| SCHEMBL13542967 | 0.76 | ALDH1A1 (0.36) | LMNATDP1ALDH1A1FABP4CA12 | |
| SCHEMBL13542948 | 0.73 | ALDH1A1 (0.36) | TSHRLMNAALDH1A1FABP4CA12 | |
| SCHEMBL13684633 | 0.72 | IDH2 (0.35) | LMNATDP1ALDH1A1FABP4CA12 | |
| SCHEMBL13687175 | 0.71 | CA12 (0.46) | LMNATDP1ALDH1A1FABP4L3MBTL1 | |
| SCHEMBL13542957 | 0.69 | NPSR1 (0.38) | LMNAALDH1A1FABP4SMN1; SMN2 | |
| SCHEMBL13545047 | 0.69 | FABP4 (0.34) | TSHRLMNATDP1ALDH1A1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | RIPK1 182/4885TSHR 3057/4885LMNA 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.